NEW YORK (GenomeWeb News) — A Blue Cross and Blue Shield Medical Advisory Panel has decided that Genomic Health’s Oncotype DX assay meets criteria set by the insurance company’s Technology Evaluation Center as a diagnostic for certain breast cancers, Genomic Health said today.

 

At a meeting last month the advisory panel concluded that the test meets its criteria for women with estrogen receptor-positive, node-negative, tamoxifen-treated breast cancer, Genomic Health said.